Survival benefit of patients with early-stage ovarian carcinoma treated with paclitaxel chemotherapeutic regimens

다국어 초록 (Multilingual Abstract)

Objective: Adjuvant chemotherapy was introduced in patients with early-stage ovarian cancer (OC). The benefit of standard chemotherapeutic regimens including taxane has not been established.
Methods: Patients with early-stage OC from the National Health Insurance Research database of Taiwan who received platinum plus cyclophosphamide (CP) or platinum plus paclitaxel (PT) for 3–6 cycles were recruited, and the disease-free survival (DFS) and overall survival (OS) were determined.
Results: A total of 1,510 early-stage OC patients, including 841 who received CP regimen and 699 who received PT regimen, were included. The 2 groups had a similar estimated probability of 5-year DFS (PT vs. CP, 79.0% vs. 77.6%; p=0.410) and OS (84.6% vs. 84.3%; p=0.691). Patients >50 years of age who received the CP regimen had a lower 5-year DFS than the patients ≤50 years of age who received the CP (p<0.001) or PT regimens (p=0.001). Additionally, patients >50 years of age who received the CP regimen had a worse 5-year OS compared with the other 3 groups (p=0.019) (p=0.179 for patients >50 years of age in the PT group; p=0.002 for patients ≤50 years of age in the CP group; and p=0.061 for patients ≤50 years of age in the PT group). Patients with the CP or PT regimen for 3–5 cycles had a similar 5-year DFS and OS compared to 6 cycles (p>0.050).
Conclusion: Chemotherapeutic regimens with taxane could be recommended for early-stage OC patients >50 years of age.

참고문헌 (Reference)

1 Dinkelspiel HE, "Use and duration of chemotherapy and its impact on survival in early-stage ovarian cancer" 137 : 203-209, 2015

2 Ying-Cheng Chiang, "Trends in incidence and survival outcome of epithelial ovarian cancer: 30-year national population-based registry in Taiwan" 대한부인종양학회 24 (24): 342-351, 2013

3 Yoshida S, "Theoretical model of treatment strategies for clear cell carcinoma of the ovary: focus on perspectives" 35 : 608-615, 2009

4 Chan JK, "The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study" 116 : 301-306, 2010

5 Health Promotion Administration, "Taiwan cancer registry annual report: 2009-2013" Ministry of Health and Welfare 2015

6 Chan JK, "Survival after recurrence in early-stage highrisk epithelial ovarian cancer: a Gynecologic Oncology Group study" 116 : 307-311, 2010

7 Chan JK, "Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?" 102 : 156-161, 2003

8 Vergote IB, "Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer" 69 : 741-749, 1992

9 Bell J, "Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study" 102 : 432-439, 2006

10 Piccart MJ, "Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results" 92 : 699-708, 2000

11 Neijt JP, "Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma" 2 : 594-600, 1984

12 Brugghe J, "Quantitative prognostic features in FIGO I ovarian cancer patients without postoperative treatment" 68 : 47-53, 1998

13 Takano M, "Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis" 12 : 256-260, 2007

14 Garcia-Saenz JA, "Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review" 13 : 121-132, 2011

15 Ozols RF, "Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study" 21 : 3194-3200, 2003

16 Chan JK, "Patterns and progress in ovarian cancer over 14 years" 108 : 521-528, 2006

17 Kurman RJ, "Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications" 27 : 151-160, 2008

18 Chan JK, "Ovarian cancer in younger vs older women: a population-based analysis" 95 : 1314-1320, 2006

19 Ahmed FY, "Natural history and prognosis of untreated stage I epithelial ovarian carcinoma" 14 : 2968-2975, 1996

20 Colombo N, "International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer" 95 : 125-132, 2003

21 Trimbos JB, "International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma" 95 : 105-112, 2003

22 Alberts DS, "Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer" 10 : 706-717, 1992

23 Trimbos JB, "Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial" 95 : 113-125, 2003

24 Farley J, "Genomic analysis of epithelial ovarian cancer" 18 : 538-548, 2008

25 Zorn KK, "Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer" 11 : 6422-6430, 2005

26 Kosary CL, "FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina" 10 : 31-46, 1994

27 Chan JK, "Differences in prognostic molecular markers between women over and under 45 years of age with advanced ovarian cancer" 10 : 8538-8543, 2004

28 McGuire WP, "Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer" 334 : 1-6, 1996

29 Stany MP, "Classification of ovarian cancer: a genomic analysis" 622 : 23-33, 2008

30 Williams CJ, "Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial" 3 : 1455-1462, 1985

31 Kolomainen DF, "Can patients with relapsed, previously untreated, stage I epithelial ovarian cancer be successfully treated with salvage therapy?" 21 : 3113-3118, 2003

32 Cabanes A, "Age-specific breast, uterine and ovarian cancer mortality trends in Spain: changes from 1980 to 2006" 33 : 169-175, 2009

33 Thigpen T, "Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience" 71 : 606-614, 1993

34 Young RC, "Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a Gynecologic Oncology Group study" 21 : 4350-4355, 2003

35 Bolis G, "Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica" 6 : 887-893, 1995

36 Young RC, "Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials" 322 : 1021-1027, 1990

37 Omura G, "A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group study" 57 : 1725-1730, 1986

38 Mannel RS, "A randomized phase III trial of IV carboplatin and paclitaxel $\times$ 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group study" 122 : 89-94, 2011

39 Ministry of Health and Welfare, "2015 Taiwan health and welfare report" Ministry of Health and Welfare

40 Mutch DG, "2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer" 133 : 401-404, 2014